| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4616 | Sb-414796 | Potent and selective dopamine D3 receptor antagonist |
|
| DCC4617 | sb-649915 | Novel 5-HT1A/B autoreceptor antagonist and serotonin reuptake inhibitor |
|
| DCC4618 | Sb-656933 | Novel CXCR2 selective antagonist, inhibiting ex vivo neutrophil activation and ozone-induced airway inflammation in humans |
|
| DCC4619 | Sb-744941 | Novel inhibitor of mitogen and Stress-Activated Kinases 1 (MSK1) |
|
| DCC4620 | Sb-7720770 Dihydrochloride | Novel Rho kinase inhibitor |
|
| DCC4621 | Sb-790594-a | Potent non-cytotoxic inhinitor of Mycobacterium tuberculosis H37Rv |
|
| DCC4622 | Sbc040 | Novel cAMP-independent potentiator of CFTR, synergistically restoring CFTR function |
|
| DCC4623 | Sbc219 | Novel cAMP-independent potentiator of CFTR, synergistically restoring CFTR function |
|
| DCC4624 | Sbfi-am | Membrane-permeant, fluorescent, selective Na+ indicator dye |
|
| DCC4625 | Sbi-0061869 | Novel potentiator of metabotropic glutamate receptors for use against neurological and psychiatric disorders |
|
| DCC4626 | Sbi-0069332 | Novel potentiator of metabotropic glutamate receptors for use against neurological and psychiatric disorders |
|
| DCC4627 | Sbi-183 | Novel inhibitor of Quiescin Sulfhydryl Oxidase 1 (QSOX1), suppresses tumor cell growth in a Matrigel-based spheroid assay and inhibits invasion in a modified Boyden chamber, but does not affect viability of non-malignant cells |
|
| DCC4628 | Sbi4211 | Inhibitor of S100B which selectively kills melanoma; Amoebicidal diamidine |
|
| DCC4629 | Sbp-0636457 | Novel Smac mimetic, demonstrating potent cell-killing effects in several subtypes of breast, ovarian, and prostate cancer cell lines but only when the DR ligand TRAIL or another such apoptosis inducer is co-administered |
|
| DCC4630 | Sc-2001 | Novel obatoclax derivative, inducing apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation |
|
| DCC4631 | Sc-203885 | Potent inhibitor of checkpoint kinase 2 (Chk2) |
|
| DCC4632 | Sc-44463 | Matrix metalloproteinase (MMP) inhibitor, also acting as a collagenase inhibitor |
|
| DCC4633 | Sc-53228 | Second-generation leukotriene B4 receptor antagonist |
|
| DCC4634 | Sc-558 | Selective COX-2 inhibitor |
|
| DCC4635 | Sc-68376 | Potent and selective inhibitor of p38 MAP kinase |
|
| DCC4636 | Sc-75416 | Novel selective COX-2 inhibitor |
|
| DCC4637 | Scacer1 | Novel photoswitchable substrate for sphingomyelin synthase 2 (SMS2), enabling optical control of apoptosis and being ready for azide-alkyne click chemistry |
|
| DCC4638 | Scacer2 | Novel photoswitchable substrate for sphingomyelin synthase 2 (SMS2), enabling optical control of apoptosis and being ready for azide-alkyne click chemistry |
|
| DCC4639 | Scalaradial | Natural Potent Inhibitor of Transient Receptor Potential Melastatin 2 (TRPM2) Ion Channels |
|
| DCC4640 | Sch-202596 | Natural selective non-peptide antagonist for the receptor GAL-1 |
|
| DCC4641 | Sch2-1-20 | Novel Inhibitor of the virus fusion to its cell receptor, targeting SARS-CoV-2 spike protein HR1 |
|
| DCC4642 | Sch2-1-27 | Novel Inhibitor of the virus fusion to its cell receptor, targeting SARS-CoV-2 spike protein HR1 |
|
| DCC4643 | Sch-23982 | Precursor for radioiosotopically labelled R(+)-SCH-23390 |
|
| DCC4644 | Sch-23985 | D1 dopamine receptor antagonist |
|
| DCC4645 | Sch-351591 | Novel, orally active phosphodiesterase 4 (PDE4) inhibitor |
|
